Abbott India Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
27165.00 -28.80 (-0.11%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
26926.35
Today’s High
27218.85
52 Week Low
21983.4
52 Week High
30499.9
27120.00 -104.35 (-0.38%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
26912.1
Today’s High
27297
52 Week Low
22000
52 Week High
30521
Key Metrics
- Market Cap (In Cr) 57849.84
- Beta 0.13
- Div. Yield (%) 1.51
- P/B 15.64
- TTM P/E 48.24
- Peg Ratio 2.22
- Sector P/E 31.15
- D/E 0.02
- Open Price 27112.15
- Prev Close 27193.8
Abbott India Analysis
Price Analysis
-
1 Week-5.22%
-
3 Months-2.14%
-
6 Month2.97%
-
YTD19.14%
-
1 Year13.55%
Risk Meter
- 22% Low risk
- 22% Moderate risk
- 22% Balanced Risk
- 22% High risk
- 22% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 2
- 2
- 2
- 2
- Buy
- 2
- 2
- 2
- 2
- Hold
- 0
- 0
- 0
- 0
- Sell
- 0
- 0
- 0
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 4
- 4
- 4
- 4
Abbott India News
Elcid Investment among India's 10 highest-priced stocks visual story
1 min read . 30 Oct 2024Torrent Pharmaceuticals, Divis Laboratories & others hit 52 week high today ; Do you own any?
3 min read . 30 Aug 2024Abbott India Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 5848.91
- Selling/ General/ Admin Expenses Total
- 576.58
- Depreciation/ Amortization
- 71.17
- Other Operating Expenses Total
- 598.62
- Total Operating Expense
- 4466.98
- Operating Income
- 1381.93
- Net Income Before Taxes
- 1617.75
- Net Income
- 1201.22
- Diluted Normalized EPS
- 565.28
- Period
- 2024
- Total Assets
- 5193.49
- Total Liabilities
- 1494.6
- Total Equity
- 3698.89
- Tangible Book Valueper Share Common Eq
- 1737.58
- Period
- 2024
- Cashfrom Operating Activities
- 1212.81
- Cashfrom Investing Activities
- -416.03
- Cashfrom Financing Activities
- -744.71
- Net Changein Cash
- 52.07
- Period
- 2023
- Total Revenue
- 5348.73
- Selling/ General/ Admin Expenses Total
- 1069.93
- Depreciation/ Amortization
- 69.97
- Other Operating Expenses Total
- 66.33
- Total Operating Expense
- 4206.75
- Operating Income
- 1141.98
- Net Income Before Taxes
- 1273.82
- Net Income
- 949.41
- Diluted Normalized EPS
- 446.68
- Period
- 2023
- Total Assets
- 4555.51
- Total Liabilities
- 1366.97
- Total Equity
- 3188.54
- Tangible Book Valueper Share Common Eq
- 1497
- Period
- 2023
- Cashfrom Operating Activities
- 893.39
- Cashfrom Investing Activities
- -147.71
- Cashfrom Financing Activities
- -638.72
- Net Changein Cash
- 106.96
- Period
- 2022
- Total Revenue
- 4919.27
- Selling/ General/ Admin Expenses Total
- 1086.89
- Depreciation/ Amortization
- 66.1
- Other Operating Expenses Total
- 57.26
- Total Operating Expense
- 3892.34
- Operating Income
- 1026.93
- Net Income Before Taxes
- 1079.73
- Net Income
- 798.7
- Diluted Normalized EPS
- 375.87
- Period
- 2022
- Total Assets
- 4224.12
- Total Liabilities
- 1404.33
- Total Equity
- 2819.79
- Tangible Book Valueper Share Common Eq
- 1322.94
- Period
- 2022
- Cashfrom Operating Activities
- 947.66
- Cashfrom Investing Activities
- -395.84
- Cashfrom Financing Activities
- -637.38
- Net Changein Cash
- -85.56
- Period
- 2021
- Total Revenue
- 4310.02
- Selling/ General/ Admin Expenses Total
- 918.82
- Depreciation/ Amortization
- 58.13
- Other Operating Expenses Total
- 53.77
- Total Operating Expense
- 3441.5
- Operating Income
- 868.52
- Net Income Before Taxes
- 925.95
- Net Income
- 690.69
- Diluted Normalized EPS
- 325.12
- Period
- 2021
- Total Assets
- 3840.45
- Total Liabilities
- 1238.29
- Total Equity
- 2602.16
- Tangible Book Valueper Share Common Eq
- 1224.04
- Period
- 2021
- Cashfrom Operating Activities
- 726.74
- Cashfrom Investing Activities
- -71.82
- Cashfrom Financing Activities
- -581.79
- Net Changein Cash
- 73.13
- Period
- 2020
- Total Revenue
- 4093.14
- Selling/ General/ Admin Expenses Total
- 929.42
- Depreciation/ Amortization
- 59.61
- Other Operating Expenses Total
- 59.3
- Total Operating Expense
- 3386.48
- Operating Income
- 706.66
- Net Income Before Taxes
- 802.69
- Net Income
- 592.93
- Diluted Normalized EPS
- 279.22
- Period
- 2020
- Total Assets
- 3546.85
- Total Liabilities
- 1115.14
- Total Equity
- 2431.71
- Tangible Book Valueper Share Common Eq
- 1143.95
- Period
- 2020
- Cashfrom Operating Activities
- 626.11
- Cashfrom Investing Activities
- -401.19
- Cashfrom Financing Activities
- -216.79
- Net Changein Cash
- 8.13
- Period
- 2019
- Total Revenue
- 3678.6
- Selling/ General/ Admin Expenses Total
- 914.55
- Depreciation/ Amortization
- 16.92
- Other Operating Expenses Total
- 47
- Total Operating Expense
- 3085.21
- Operating Income
- 593.4
- Net Income Before Taxes
- 698.85
- Net Income
- 450.33
- Diluted Normalized EPS
- 209
- Period
- 2019
- Total Assets
- 2940.91
- Total Liabilities
- 932.33
- Total Equity
- 2008.59
- Tangible Book Valueper Share Common Eq
- 944.38
- Period
- 2019
- Cashfrom Operating Activities
- 499.13
- Cashfrom Investing Activities
- -257
- Cashfrom Financing Activities
- -142.8
- Net Changein Cash
- 99.33
- Period
- 2024-09-30
- Total Revenue
- 1632.67
- Selling/ General/ Admin Expenses Total
- 147.4
- Depreciation/ Amortization
- 17.51
- Other Operating Expenses Total
- 144.55
- Total Operating Expense
- 1211.22
- Operating Income
- 421.45
- Net Income Before Taxes
- 479.43
- Net Income
- 358.61
- Diluted Normalized EPS
- 168.76
- Period
- 2024-09-30
- Total Assets
- 5063.02
- Total Liabilities
- 1541.91
- Total Equity
- 3521.11
- Tangible Book Valueper Share Common Eq
- 1653.31
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 481.95
- Cashfrom Investing Activities
- 762.53
- Cashfrom Financing Activities
- -898.53
- Net Changein Cash
- 345.95
- Period
- 2024-06-30
- Total Revenue
- 1557.61
- Selling/ General/ Admin Expenses Total
- 161.06
- Depreciation/ Amortization
- 18.37
- Other Operating Expenses Total
- 159.18
- Total Operating Expense
- 1184.97
- Operating Income
- 372.64
- Net Income Before Taxes
- 437.22
- Net Income
- 328.01
- Diluted Normalized EPS
- 154.36
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1438.63
- Selling/ General/ Admin Expenses Total
- 145.24
- Depreciation/ Amortization
- 18.19
- Other Operating Expenses Total
- 157.96
- Total Operating Expense
- 1127.29
- Operating Income
- 311.34
- Net Income Before Taxes
- 389.68
- Net Income
- 287.06
- Diluted Normalized EPS
- 135.09
- Period
- 2024-03-31
- Total Assets
- 5193.49
- Total Liabilities
- 1494.6
- Total Equity
- 3698.89
- Tangible Book Valueper Share Common Eq
- 1737.58
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1212.81
- Cashfrom Investing Activities
- -416.03
- Cashfrom Financing Activities
- -744.71
- Net Changein Cash
- 52.07
- Period
- 2023-12-31
- Total Revenue
- 1437.14
- Selling/ General/ Admin Expenses Total
- 139.19
- Depreciation/ Amortization
- 17.97
- Other Operating Expenses Total
- 133.47
- Total Operating Expense
- 1067.42
- Operating Income
- 369.72
- Net Income Before Taxes
- 422.16
- Net Income
- 310.98
- Diluted Normalized EPS
- 146.34
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 1494.14
- Selling/ General/ Admin Expenses Total
- 142.7
- Depreciation/ Amortization
- 17.84
- Other Operating Expenses Total
- 156.21
- Total Operating Expense
- 1131.1
- Operating Income
- 363.04
- Net Income Before Taxes
- 415.42
- Net Income
- 312.94
- Diluted Normalized EPS
- 147.27
- Period
- 2023-09-30
- Total Assets
- 4515.94
- Total Liabilities
- 1407.02
- Total Equity
- 3108.92
- Tangible Book Valueper Share Common Eq
- 1459.82
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 683.63
- Cashfrom Investing Activities
- 372.22
- Cashfrom Financing Activities
- -717.39
- Net Changein Cash
- 338.46
- Period
- 2023-06-30
- Total Revenue
- 1479
- Selling/ General/ Admin Expenses Total
- 149.45
- Depreciation/ Amortization
- 17.17
- Other Operating Expenses Total
- 150.98
- Total Operating Expense
- 1141.17
- Operating Income
- 337.83
- Net Income Before Taxes
- 390.49
- Net Income
- 290.24
- Diluted Normalized EPS
- 136.58
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 1338.4
- Selling/ General/ Admin Expenses Total
- 126.7
- Depreciation/ Amortization
- 17.34
- Other Operating Expenses Total
- 176.2
- Total Operating Expense
- 1080.3
- Operating Income
- 258.1
- Net Income Before Taxes
- 308.41
- Net Income
- 231.42
- Diluted Normalized EPS
- 108.92
- Period
- 2023-03-31
- Total Assets
- 4555.51
- Total Liabilities
- 1366.97
- Total Equity
- 3188.54
- Tangible Book Valueper Share Common Eq
- 1497
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 893.39
- Cashfrom Investing Activities
- -147.71
- Cashfrom Financing Activities
- -638.72
- Net Changein Cash
- 106.96
- Period
- 2022-12-31
- Total Revenue
- 1326.48
- Selling/ General/ Admin Expenses Total
- 135.24
- Depreciation/ Amortization
- 17.81
- Other Operating Expenses Total
- 129.89
- Total Operating Expense
- 1027.8
- Operating Income
- 298.68
- Net Income Before Taxes
- 334.83
- Net Income
- 246.83
- Diluted Normalized EPS
- 116.16
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Abbott India Technical
Moving Average
SMA
- 5 Day27893.24
- 10 Day28422.4
- 20 Day28581.38
- 50 Day28773.01
- 100 Day28462
- 300 Day27776.05
Abbott India Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Lupin
- 889.05
- 8.25
- 0.94
- 889.9
- 602.8
- 40512.13
- Alkem Laboratories
- 5601
- 75.75
- 1.37
- 6440
- 4382.25
- 66959.96
- Abbott India
- 27165
- -28.8
- -0.11
- 30499.9
- 21983.4
- 57723.72
- Glenmark Pharmaceuticals
- 1464.9
- -27.45
- -1.84
- 1830.05
- 761.15
- 41338.01
- Glaxosmithkline Pharmaceuticals
- 2376.5
- -59.75
- -2.45
- 3073.87
- 1557.92
- 40259.34
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Lupin
- 44.93
- 6.5
- 2.51
- 2.04
- Alkem Laboratories
- 36.76
- 6.41
- 18.26
- 13.94
- Abbott India
- 48.16
- 15.64
- 30.46
- 17.26
- Glenmark Pharmaceuticals
- -
- 5.37
- 1.61
- 1.43
- Glaxosmithkline Pharmaceuticals
- 59.59
- 23.23
- 20.45
- 12.25
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 07-Nov-24
- Quarterly Results
- 07-Aug-24
- Quarterly Results
- 09-May-24
- Audited Results & Final Dividend
- 01-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 09-Aug-23
- Quarterly Results
- 19-May-23
- Audited Results & Final Dividend
- 10-Feb-23
- Quarterly Results
- 14-Nov-22
- Quarterly Results
- 10-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 08-Aug-24
- 09-May-24
- AGM
- 09-Aug-23
- 19-May-23
- AGM
- 10-Aug-22
- 17-May-22
- AGM
- 28-Mar-22
- 23-Feb-22
- POM
- 27-Jul-21
- 18-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 09-May-24
- 19-Jul-24
- 19-Jul-24
- 410
- 19-May-23
- 21-Jul-23
- 21-Jul-23
- 180
- 20-May-23
- 21-Jul-23
- 21-Jul-23
- 145
- 17-May-22
- -
- 02-Aug-22
- 145
- 18-May-22
- -
- 02-Aug-22
- 130
- 18-May-21
- -
- 19-Jul-21
- 120
- 19-May-21
- -
- 19-Jul-21
- 155